Capricor Therapeutics Reports Long-Term Data From HOPE-2 OLE Study In Duchenne Muscular Dystrophy At 2024 World Muscle Society Congress
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics presented long-term data from the HOPE-2 OLE study at the 2024 World Muscle Society Congress, showing sustained efficacy and safety of Deramiocel in treating Duchenne Muscular Dystrophy. The company plans to submit a Biologics License Application by the end of 2024.
October 11, 2024 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Capricor Therapeutics' long-term data from the HOPE-2 OLE study shows sustained efficacy and safety of Deramiocel in treating Duchenne Muscular Dystrophy, with plans to submit a BLA by the end of 2024.
The positive long-term data supports the efficacy and safety of Deramiocel, which is crucial for the upcoming BLA submission. This progress is likely to boost investor confidence and positively impact CAPR's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100